Pipeline

Our targeted multi-cancer panels track epigenomic signals to detect the disease early.

The ClearNote Health approach to detecting cancer early is anchored in epigenomics by tracking changes in cells in the body. With the current focus on pancreatic and ovarian cancers, we aim to address unmet patient needs through early and focused cancer detection through a simple blood draw. Unlike existing cancer screening methods, our 5hmC-based proprietary technology platform provides a comprehensive view of tumor biology to inform patient diagnosis and treatment journey. Our R&D pipeline includes multiple single-cancer and focused multi-cancer tests to help people at high risk of developing high-mortality cancers live longer and healthier lives.

ClearNote Health is committed to supporting cancer patients wherever they are in their cancer journey starting with early detection.

We are also exploring multiple applications for our epigenomics technology platform to assist clinicians with therapy selection, therapy monitoring and detection of cancer recurrence. Throughout the process of early cancer detection, diagnosis and treatment, clinicians and patients require ongoing monitoring of the disease.

Tracking Epigenomic Signals To Detect Cancer

ClearNote Health
Privacy Overview

We use cookies, subject to your consent, to analyze the use of our website and to ensure you get the best experience. Third parties with whom we collaborate can also install cookies in order to show you personalized advertisements on other websites. Read our cookie policy for more information.
Read our privacy policy to understand how ClearNote Health handles personal information that we collect through our digital properties that link to this Privacy Policy, including our website and other activities described in the privacy policy.